Cancer Genetics – About the Company
The Company has five molecular diagnostics products on the market across three major platforms. The first platform is Mature B-cell Neoplasm Array (MatBA®), a proprietary oligonucleotide array that can detect chromosomal gains and losses at 80 specific genomic sites. MatBA is approved for three types of non-Hodgkin lymphomas. UroGenRA™ is a proprietary oligonucleotide array designed to detect genomic copy number alterations in urogenital cancer cells. The last platform is FISH-based HPV-Associated Cancer Test (FHACT™), a fluorescence in situ hybridization method to detect specific chromosomal amplifications. FHACT is approved for cervical cancer screening.
Cancer Genetics is continuing to develop additional products based on its three core diagnostic platforms. The development pipeline includes two new indications for MatBA, five new indications for UroGenRA, and one new indication for FHACT. The Company has partnerships with leading research institutions such as Memorial Sloan Kettering and the Mayo Clinic to facilitate product expansion and develop the next -generation of diagnostic tools.